Jasper Therapeutics, Inc.

Develops mast cell-depleting antibody therapies for chronic diseases and stem cell transplants.

JSPR | US

Overview

Corporate Details

ISIN(s):: US4718712023 (+3 more)
LEI:
Country:: United States of America
Address:: 2200 BRIDGE PKWY SUITE #102, 94065 REDWOOD CITY
Website:: https://jaspertx.com/
Sector:: Manufacturing
Industry:: Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Jasper Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing therapies for mast cell-driven diseases and as a conditioning agent for hematopoietic stem cell transplantation. The company's lead product candidate is briquilimab, a targeted anti-KIT (CD117) monoclonal antibody designed to deplete mast cells. Jasper is evaluating briquilimab in clinical studies for the treatment of chronic immunological and inflammatory diseases, including chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU), and allergic asthma. The company's mission is to develop safer and more effective therapies for patients with serious chronic diseases by harnessing the power of mast cell depletion.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Quick Filters:

Filters

Filing Type

Language

Start date

End date

Clear

Bulk Actions:

	Date	Filing	Language	Size	Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Jasper Therapeutics, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Jasper Therapeutics, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Request This Data

Need More History? Access decades of standardized financials for Jasper Therapeutics, Inc. via our API.

Get Historical Data →

Insider Transactions

Date	Insider Name	Position	Type	Shares	Value
No insider transactions recorded for this company.

Peer Companies

Company	Country	Ticker
Novo Nordisk Develops medicines and devices for chronic diseases like diabetes, obesity, and rare disorders.	Denmark	NOVO
NRX Pharmaceuticals, Inc. Develops novel oral drugs for CNS disorders, targeting suicidal depression and PTSD.	United States of America	NRXP
NuCana plc Develops safer anti-cancer medicines with ProTide technology to overcome cell resistance.	United States of America	NCNA
NUFORMIX PLC Repurposing drugs for fibrosis and oncology using proprietary cocrystal technology.	United Kingdom	NFX
Nurix Therapeutics, Inc. Developing protein degradation medicines to treat cancer and autoimmune diseases.	United States of America	NRIX
NUTEX Investments Plc Develops & distributes health, cosmetic & pharma products from natural ingredients globally.	Hungary	NUTEX
NutriBand Inc. Develops abuse-deterrent transdermal patches to make potent drug delivery safer.	United States of America	NTRB
Nuvalent, Inc. Designs targeted small molecule drugs for kinase-driven cancers to overcome treatment resistance.	United States of America	NUVL
Nuvation Bio Inc. A clinical-stage biopharma developing novel drugs for difficult-to-treat cancers.	United States of America	NUVB
Nxera Pharma Co., Ltd. Biopharma using SBDD tech to develop medicines for neurology and gastroenterology.	Japan	4565